Rheumatology and immunology research最新文献

{"title":"Consensus on targeted drug therapy for spondyloarthritis.","authors":"Xinping Tian,&nbsp;Mengtao Li,&nbsp;Shengyun Liu,&nbsp;Xiaomei Leng,&nbsp;Qian Wang,&nbsp;Jiuliang Zhao,&nbsp;Yi Liu,&nbsp;Yan Zhao,&nbsp;Yizhi Zhang,&nbsp;Huji Xu,&nbsp;Jieruo Gu,&nbsp;Xiaofeng Zeng","doi":"10.2478/rir-2023-0009","DOIUrl":"https://doi.org/10.2478/rir-2023-0009","url":null,"abstract":"<p><p>Spondyloarthritis (SpA) is a group of chronic inflammatory diseases that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are highly heterogenous and complicated with various comorbidities. SpA is a disabling disease and adversely affects the quality of life of patients. Many new medications that target cytokines or pathways specific for the pathogenesis of SpA have been developed and they are becoming increasingly important in the treatment of SpA. However, identifying the target patient population and standardizing the usage of these drugs are critical issues in the clinical application of these \"targeted therapeutic drugs\". Under the leadership of National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), managed by Peking Union Medical College Hospital, the \"Consensus on targeted drug therapy for spondyloarthritis\" has been developed in collaboration with the Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association, Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine, and Chinese Research Hospital Association Rheumatology and Immunology Professional Committee. This consensus has been developed with evidence-based methodology and has followed the international standard for consensus development.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 2","pages":"47-59"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10456589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new bed side test for inflammatory arthritis.","authors":"Saba Samreen,&nbsp;Babur Salim,&nbsp;Haris Gul,&nbsp;Shahida Parveen","doi":"10.2478/rir-2023-0016","DOIUrl":"https://doi.org/10.2478/rir-2023-0016","url":null,"abstract":"E-mail: sabasamreen@hotmail.com. https://orcid.org/0000-0002-7320-4739 Inflammatory arthritis is characterized by pain, swelling and early morning stiffness in the affected joints. This group of arthritis have the propensity to lead to erosions and joint damage.[1] The resulting joint damage and functional disability not only leads to morbidity but adds to the burden on health care infrastructure. This is an area of particular concern especially in developing countries where the health care facilities and budget is scarce.[2] There are several tools to detect synovitis. Out of these magnetic resonance imaging (MRI) has a fair sensitivity and specificity but cost hampers it is regular use in daily practice especially in developing countries. Similarly musculoskeletal ultrasound also picks up synovitis early in the disease with acceptable sensitivity and specificity[3] but it is not yet commonly available in all setups. Therefore, we need to maximally rely on examination skills especially in developing countries. Timely diagnosis of synovitis and prompt initiation of treatment[4] is the key to better patient related outcomes.","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 2","pages":"104-106"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10456590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis.","authors":"Marriam Hussain Awan,&nbsp;Saba Samreen,&nbsp;Shahida Perveen,&nbsp;Babur Salim,&nbsp;Haris Gul,&nbsp;Anum Khan","doi":"10.2478/rir-2023-0014","DOIUrl":"https://doi.org/10.2478/rir-2023-0014","url":null,"abstract":"<p><p>Rituximab, a murine-human chimeric monoclonal antibody targeting CD20-positive B lymphocytes, has established itself as an effective and relatively safe biologic therapy for patients with refractory rheumatoid arthritis. Most common side effects associated with its use include infusion related reactions and cytopenia. Rare adverse effects such as progressive multifocal leukoencephalopathy and posterior reversible encephalopathy syndrome (PRES) have also been reported. Diagnosis of PRES following rituximab treatment requires a high index of suspicion correlated with clinical and radiological features in individuals at risk. Early diagnosis and prompt treatment is associated with a favorable prognosis. We present a case of a young man who developed PRES following rituximab administration on account of active rheumatoid arthritis. Timely diagnosis and prompt treatment ensured his uneventful recovery without residual neurological deficit.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 2","pages":"98-101"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10456588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypermobility spectrum disorders: A review.","authors":"Matthew B Carroll","doi":"10.2478/rir-2023-0010","DOIUrl":"https://doi.org/10.2478/rir-2023-0010","url":null,"abstract":"<p><p>It remains a clinical challenge identifying when joint hypermobility (JH) is responsible for pain. Previous nomenclature utilized terms such as (benign) joint hypermobility syndrome (JHS) but this was updated in 2017 as advances in genetics provide a basis for nearly all variants of Ehlers-Danlos syndrome (EDS) with the exception of hypermobile EDS (hEDS). New terminology describes hypermobility spectrum disorders (HSDs) as the updated term for JHS. Diagnosis of a subtype of HSDs should be considered in patients who have JH coupled with the presence of secondary musculo-skeletal manifestations (trauma, chronic pain, disturbed proprioception, and other manifestations) and at the exclusion of hEDS. Extra-articular manifestations are common. Treatment relies on management strategies for other chronic pain syndromes with a multidisciplinary approach likely optimal. Lifestyle modifications focus on weight loss and exercise. Physical therapy helps strengthen periarticular muscles, improving mobility. Pharmacologic therapies focus on judicious use of non-steroidal anti-inflammatory drugs and acetaminophen. Serotonin and norepinephrine reuptake inhibitor may help widespread pain. Avoidance of opioids remains prudent. The purpose of this review is to provide clinicians the rationale for the update in nomenclature, understand the musculoskeletal and extra-articular manifestations of the subtypes of HSDs, considerations when making the diagnosis, and treatment.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 2","pages":"60-68"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A survey of artificial intelligence in rheumatoid arthritis.","authors":"Jiaqi Wang,&nbsp;Yu Tian,&nbsp;Tianshu Zhou,&nbsp;Danyang Tong,&nbsp;Jing Ma,&nbsp;Jingsong Li","doi":"10.2478/rir-2023-0011","DOIUrl":"https://doi.org/10.2478/rir-2023-0011","url":null,"abstract":"<p><p>The article offers a survey of currently notable artificial intelligence methods (released between 2019-2023), with a particular emphasis on the latest advancements in detecting rheumatoid arthritis (RA) at an early stage, providing early treatment, and managing the disease. We discussed challenges in these areas followed by specific artificial intelligence (AI) techniques and summarized advances, relevant strengths, and obstacles. Overall, the application of AI in the fields of RA has the potential to enable healthcare professionals to detect RA at an earlier stage, thereby facilitating timely intervention and better disease management. However, more research is required to confirm the precision and dependability of AI in RA, and several problems such as technological and ethical concerns related to these approaches must be resolved before their widespread adoption.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 2","pages":"69-77"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10475410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus with initial mesenteric vasculitis.","authors":"Jing-Jing Xie,&nbsp;Gui-Chen Ling,&nbsp;Yu-Bao Jiang,&nbsp;Jian-Yong Zhang","doi":"10.2478/rir-2023-0015","DOIUrl":"https://doi.org/10.2478/rir-2023-0015","url":null,"abstract":"A 39-year-old woman was admitted because of abdominal pain, nausea, and vomiting after meals for 2 days. She also had fecal incontinence, urination frequency, and urgency for 4 days. She had no specific past medical history. Physical examination revealed diffuse abdominal distension, tender - ness below the sternum, and rebound pain without rigidity. Laboratory tests showed mild anemia, positive homogeneous pattern antinuclear antibody (ANA) with a titer of 1:320, she was also positive for anti-U1-RNP antibodies, anti-double-stranded DNA antibodies, anti-nucleosome antibodies, anti-SSA antibodies, anti-RO-52 antibodies, and anti-histone antibodies, with decreased complements levels. Her D-dimer was 2745 μ g/L. Enhanced computed tomography of the abdomen revealed diffuse circumferential wall thickening with submucosal edema of the entire small bowel, accompanied by ascites. “Fence-like” changes of mesenteric vessels with dilatation of bowel loops, thickened bowel walls, and the “double-halo” sign or “target” sign were observed","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 2","pages":"102-103"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9865677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to \"Social media for research discourse, dissemination, and collaboration in rheumatology\".","authors":"Ariella Coler-Reilly,&nbsp;Elizabeth R Graef,&nbsp;Alfred H J Kim,&nbsp;Jean W Liew,&nbsp;Michael S Putman,&nbsp;Sebastian E Sattui,&nbsp;Kristen J Young,&nbsp;Jeffrey A Sparks","doi":"10.2478/rir-2023-0017","DOIUrl":"https://doi.org/10.2478/rir-2023-0017","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 2","pages":"107-108"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10139750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual presentation of a mass and \"cobble-stone like\" changes in the bronchus of a patient with granulomatosis with polyangitis.","authors":"Ping Fan,&nbsp;Zhiming Hao,&nbsp;Peilong Cao,&nbsp;Lan He","doi":"10.2478/rir-2023-0007","DOIUrl":"https://doi.org/10.2478/rir-2023-0007","url":null,"abstract":"A 44-year-old male was diagnosed with granulomatosis with polyangiitis (GPA) 1 year ago because of intermittent cough, short of breath, epistaxis, hearing loss and a positive protein-ase-3 anti-neutrophilic cytoplasmatic antibody (PR3-ANCA) test. After being treated with oral prednisone, cyclophospha-mide for a year, he was hospitalized due to reappearance of cough and epistaxis. The nasopharyngoscopy showed extensive necrosis of the left nasal cavity. The biopsy of nasal cavity mucosa revealed fibrinoid necrotizing vasculitis","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 1","pages":"44-45"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/d1/rir-4-1-rir-2023-0007.PMC10150860.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9411901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine-associated autoimmune disorders: Comments.","authors":"Amnuay Kleebayoon,&nbsp;Viroj Wiwanitkit","doi":"10.2478/rir-2023-0008","DOIUrl":"https://doi.org/10.2478/rir-2023-0008","url":null,"abstract":"We would like to comment on the article “Corona Virus Disease-19 Vaccine-associated Autoimmune Disorders”.[1] Awan et al. attempt to summarize the various autoimmune phenomena reported after corona virus disease 2019 (COVID-19) vaccination in order to sensitize the medical community so that they can better manage these diseases when confronted with them.[1] According to Awan et al., this review in no way negates the potential benefit of COVID-19 vaccination, which has cemented its place in preventing infections and significantly reducing severity and mortality.[1]","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 1","pages":"46"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/9a/rir-4-1-rir-2023-0008.PMC10150862.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9411899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and vascular features of stroke in Takayasu's arteritis: A 24-year retrospective study.","authors":"Guizhi Zhang,&nbsp;Jun Ni,&nbsp;Yunjiao Yang,&nbsp;Jing Li,&nbsp;Xinping Tian,&nbsp;Xiaofeng Zeng","doi":"10.2478/rir-2023-0004","DOIUrl":"https://doi.org/10.2478/rir-2023-0004","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics, vascular imaging features, and prognosis of Takayasu's arteritis (TA) patients with stroke in China.</p><p><strong>Methods: </strong>Medical charts of 411 in-patients who fulfilled the classification criteria of modified 1990 American College of Rheumatology (ACR) criteria for TA and with complete data from 1990 to 2014 were reviewed retrospectively. The demographic data, symptoms and signs, laboratory test results, radiological features, treatment, and interventional or surgical procedures were collected and analyzed. Patients with radiological confirmed stroke were identified. Chi-square test or Fisher exact test was used to compare the differences between patients with and without stroke.</p><p><strong>Results: </strong>Twenty-two patients with ischemic stroke (IS) and 4 patients with hemorrhagic stroke were identified. The incidence of stroke in TA patients was 6.3% (26/411), of which 11 patients were considered to be the initial manifestation. Stroke patients had more visual acuity loss (15.4% vs. 4.7%, <i>P</i> = 0.042). Systemic inflammatory symptoms and inflammatory markers were less common in patients with stroke than in those without stroke [fever <i>P</i> = 0.007; erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), <i>P</i> < 0.001]. Cranial angiography showed that common carotid artery (CCA) (73.0%, 19/26) and subclavian artery (SCA) (73.0%, 19/26) were the most involved, followed by internal carotid artery (ICA) (57.7%, 15/26) in stroke patients. The intracranial vascular involvement rate of stroke patients was 38.5% (10/26); the middle cerebral artery (MCA) was the most common artery involved. The most common site of stroke was the basal ganglia region. The occurrence of intracranial vascular involvement was much higher in patients with stroke when compared to patients without stroke (38.5% vs. 5.5%, <i>P <</i> 0.001). Among all patients with intracranial vascular involvement, patients without stroke received more aggressive treatment than patients with stroke (90.4% vs. 20.0%, <i>P <</i> 0.001). There was no significant increase in in-hospital mortality in patients with stroke compared with patients without stroke (3.8% vs. 2.3%, <i>P</i> = 0.629).</p><p><strong>Conclusion: </strong>Stroke is the initial presentation in 50% of TA patients with stroke. The intracranial vascular involvement rate is significantly increased in stroke patients than in patients without stroke. The artery invloved in patients with stroke are cervical artery and intracranial involvement. Systemic inflammation is less in patients with stroke. Aggressive treatment for TA with glucosteroid (GC) and immunosuppressive agents combined with anti-stroke therapy is needed to improve the prognosis of TA complicated stroke.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 1","pages":"22-29"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/8a/rir-4-1-rir-2023-0004.PMC10150874.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9411897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}